Sandu Pharmaceuticals Board Meeting Date
Sandu Pharmaceuticals scheduled a board meeting on November 14, 2026, to approve unaudited financial results. The meeting covers the quarter and half-year ended September 30, 2026.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Sandu Pharmaceuticals scheduled a board meeting on November 14, 2026, to approve unaudited financial results. The meeting covers the quarter and half-year ended September 30, 2026.
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Limited has filed its 41st Annual Report for the financial year 2025-26, including the notice for the upcoming 41st Annual General Meeting.
Sandu Pharmaceuticals announced its 41st Annual General Meeting scheduled for September 11, 2026. The notice includes resolutions for dividend declaration and board appointments.